Clinical Trials
Recent cancer clinical trials sourced from ClinicalTrials.gov. Trials are listed for informational purposes only. Always consult your healthcare provider before making decisions about clinical trial participation.
HA-1 T TCR T Cell ImmunotherapyTreatments that use the body's immune system to fight cancer.Click for full explanation → for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Conditions: Juvenile Myelomonocytic Leukemia, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Undifferentiated Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Adult Acute Lymphoblastic Leukemia, Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm, Recurrent Myelodysplastic Syndrome, Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm, Refractory Myelodysplastic Syndrome, Acute Undifferentiated Leukemia, Mixed Phenotype Acute Leukemia, Recurrent Chronic Myeloid Leukemia, BCR-ABL1 Positive, Refractory Chronic Myeloid Leukemia, BCR-ABL1 Positive, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Biphenotypic Leukemia, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Minimal Residual Disease, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Leukemia, Chronic Myeloid Leukemia, BCR-ABL1 Positive
Interventions: CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR, Bone Marrow Aspiration, Biospecimen Collection
NCT03326921 - View on ClinicalTrials.gov →Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial
Conditions: Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
Interventions: Acalabrutinib, Venetoclax, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging
NCT04941716 - View on ClinicalTrials.gov →CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)
Conditions: Refractory B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Small Lymphocytic Lymphoma, Relapsed Adult ALL, Relapsed CLL, Relapsed Non Hodgkin Lymphoma
Interventions: CD19.CAR-aNKT cells
NCT03774654 - View on ClinicalTrials.gov →Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Conditions: Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Interventions: Nemtabrutinib, Lisocabtagene Maraleucel
NCT07194980 - View on ClinicalTrials.gov →Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Conditions: Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
Interventions: AU-007, Aldesleukin, Avelumab, Nivolumab
NCT05267626 - View on ClinicalTrials.gov →Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases
Conditions: Melanoma, Brain Metastases
Interventions: Ipilimumab, Nivolumab + Relatlimab FDC
NCT06712927 - View on ClinicalTrials.gov →A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer
Conditions: Pancreatic Cancer Metastatic
Interventions: Regorafenib combined with Toripalimab and Albumin paclitaxel
NCT07040228 - View on ClinicalTrials.gov →Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer
Conditions: Metastatic Colorectal Cancer, Advanced Colorectal Cancer
Interventions: RBS2418, Placebo
NCT06824064 - View on ClinicalTrials.gov →A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)
Conditions: Non-metastatic Castration-resistant Prostate Cancer
Interventions: Darolutamide (Nubeqa, BAY1841788)
NCT05348876 - View on ClinicalTrials.gov →KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without ChemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Pembrolizumab, Carboplatin, Paclitaxel, Pemetrexed, Vibostolimab, Boserolimab, MK-4830, MK-0482, Ifinatamab Deruxtecan (I-DXd), HER3-DXd
NCT04165070 - View on ClinicalTrials.gov →KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS ChemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Tumor Imaging, Tumor Tissue Collection, Blood Sample Collection
NCT04165798 - View on ClinicalTrials.gov →A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Conditions: Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer, Squamous Non-Small Cell Lung Cancer
Interventions: AZD8205, AZD8205 and AZD2936 (Rilvegostomig), AZD8205 and AZD5305 (saruparib), AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig), AZD8205 in combination with AZD9574, AZD8205 in combination with AZD9574 plus rilvegostomig (AZD2936)
NCT05123482 - View on ClinicalTrials.gov →A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →- Advanced Breast Cancer
Conditions: Advanced Breast Cancer
Interventions: ZOLADEX
NCT07310420 - View on ClinicalTrials.gov →The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Conditions: Amyloidosis, Basal Cell Carcinoma, Biliary Tract Carcinoma, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Fallopian Tube Carcinoma, Gastroesophageal Junction Carcinoma, Glioblastoma, Head and Neck Carcinoma, Hematopoietic and Lymphatic System Neoplasm, Hepatocellular Carcinoma, Hodgkin Lymphoma, Lung Carcinoma, Malignant Solid Neoplasm, Mantle Cell Lymphoma, Melanoma, Merkel Cell Carcinoma, Multiple Myeloma, Myelodysplastic Syndrome, Ovarian Carcinoma, Pancreatic Carcinoma, Primary Peritoneal Carcinoma, Prostate Carcinoma, Renal Cell Carcinoma, Squamous Cell Carcinoma, Urothelial Carcinoma
Interventions: Cancer Therapeutic Procedure, Cancer Therapeutic Procedure, Questionnaire Administration
NCT07285044 - View on ClinicalTrials.gov →Impact of Web Application Support Versus Standard Management on Compliance With Adjuvant Hormone TherapyTreatments that reduce or block hormones that fuel certain cancers.Click for full explanation → at 18 Months in Patients Treated for Breast Cancer
Conditions: Web-application, Breast Cancer, Hormono Therapy
Interventions: WEB-Application, Standard accompaniment
NCT04554927 - View on ClinicalTrials.gov →A Trial of LBL-024 Monotherapy, LBL-024 Combined With LBL-007 or Toripalimab in Patients With Advanced Melanoma
Conditions: Advanced Melanoma
Interventions: LBL-024 for Injection, LBL-007 Injection, Toripalimab Injection
NCT07099430 - View on ClinicalTrials.gov →A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer
Conditions: Prostate Cancer, Prostate Adenocarcinoma, Localized Prostate Carcinoma
Interventions: Exercise Therapy
NCT05751434 - View on ClinicalTrials.gov →CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Conditions: Acute Lymphoblastic Leukemia, B-All
Interventions: CD22 CAR-transduced T cells, Cyclophosphamide, Fludarabine
NCT07328503 - View on ClinicalTrials.gov →Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women
Conditions: Uterine Cancer, Rectal Cancer, Colon Cancer, Breast Cancer, Lung Cancer, Sarcoma, Cervix Cancer, Head and Neck Cancer, Anal Cancer, Liver Cancer, Gastric Cancer, Bladder Cancer
Interventions: HyperSight cone beam computed tomography (CBCT) scan, ETHOS 2.0
NCT06904365 - View on ClinicalTrials.gov →A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Conditions: Melanoma, Lymphoma, Solid Tumor, Classical Hodgkin Lymphoma, Microsatellite-instability-high Solid Tumor
Interventions: Pembrolizumab
NCT02332668 - View on ClinicalTrials.gov →BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
Conditions: Colorectal Cancer, Pancreatic Cancer, Gastric Cancers, Cholangiocarcinoma
Interventions: BOLD-100 +/- FOLFOX ChemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → (Arm VII), BOLD-100 in combination with FOLFOX ChemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → (Arms I-VI)
NCT04421820 - View on ClinicalTrials.gov →Social and Environmental Determinants of Breast Cancer Survivorship: the Black Breast Cancer Survivor's Intervention (BBCSI)
Conditions: Breast Cancer
Interventions: Black Breast Cancer Survivor's Intervention
NCT06885203 - View on ClinicalTrials.gov →A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation → G12D MutationA change in DNA sequence that can drive cancer development.Click for full explanation →
Conditions: Advanced/Metastatic Colorectal Adenocarcinoma
Interventions: BAY 3771249, Cetuximab
NCT07535112 - View on ClinicalTrials.gov →A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
Conditions: Non-Small Cell Lung Cancer
Interventions: Durvalumab, Domvanalimab, Placebo
NCT05211895 - View on ClinicalTrials.gov →A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
Conditions: Advanced Prostate Cancer, Metastatic Prostate Cancer
Interventions: RO7656594
NCT05800665 - View on ClinicalTrials.gov →A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRASOne of the most common cancer-driving mutations, found in lung, colon, and pancreatic cancers.Click for full explanation → G12C MutationA change in DNA sequence that can drive cancer development.Click for full explanation →
Conditions: Non-Small Cell Lung Cancer
Interventions: Divarasib, Pembrolizumab, Carboplatin, Cisplatin, Pemetrexed
NCT05789082 - View on ClinicalTrials.gov →A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: BAY3546828
NCT06052306 - View on ClinicalTrials.gov →A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With MutationsA change in DNA sequence that can drive cancer development.Click for full explanation → of the Human Epidermal Growth Factor Receptor 2 (HER2A protein that promotes cell growth — overexpressed in some breast and stomach cancers.Click for full explanation →)
Conditions: Advanced Non-small Cell Lung Cancer, HER2 Mutation
Interventions: Sevabertinib, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed
NCT06452277 - View on ClinicalTrials.gov →Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
Conditions: Chronic Lymphocytic Leukaemia, Heart Failure
Interventions: Acalabrutinib, Investigator's choice of treatment
NCT06651970 - View on ClinicalTrials.gov →A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
Conditions: Tumor Hyperinsulinism (Tumor HI)
Interventions: Ersodetug
NCT06881992 - View on ClinicalTrials.gov →An Observational Study to Learn More About How Medicines That Block Male Hormones Are Used in People With Prostate Cancer in Australia
Conditions: Metastatic Hormonesensitive Prostate Cancer (mHSPC)
NCT07223372 - View on ClinicalTrials.gov →Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
Conditions: Lung Neoplasm
Interventions: R-DXD, I-DXD, Docetaxel, Rescue Medications, Rescue Medication
NCT06780098 - View on ClinicalTrials.gov →A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer
Conditions: Colorectal Cancer
Interventions: ONO-4578, Opdivo®, Oxaliplatin, 5-Fluorouracil, Bevacizumab, Leucovorin
NCT06948448 - View on ClinicalTrials.gov →Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
Conditions: Advanced Solid Tumors
Interventions: M7437, M7437
NCT07360314 - View on ClinicalTrials.gov →A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia
Conditions: Acute Lymphoblastic Leukemia
Interventions: Obecabtagene Autoleucel
NCT07400029 - View on ClinicalTrials.gov →Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma
Conditions: PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
Interventions: Breath test, Collection of matched samples of breath, biofluids and pancreatic tissue
NCT05727020 - View on ClinicalTrials.gov →A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Conditions: Solid Tumor, Non-Small-Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
Interventions: ASP5834, panitumumab
NCT07094204 - View on ClinicalTrials.gov →A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP InhibitorsDrugs that block PARP enzymes, exploiting DNA repair defects in cancer cells such as those with BRCA mutations.Click for full explanation →
Conditions: HRD Cancer, SCLC, Advanced Solid Tumors
Interventions: Berzosertib, Sacituzumab Govitecan
NCT04826341 - View on ClinicalTrials.gov →A First-in-human Study to Learn How Safe BAY 3713372 is and How it Works in Participants With MTAP-deleted Solid Tumors
Conditions: MTAP-deleted Solid Tumors
Interventions: BAY 3713372
NCT06914128 - View on ClinicalTrials.gov →A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and ChemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → Versus Placebo Plus Pembrolizumab and ChemotherapyDrugs that kill rapidly dividing cells, including cancer cells.Click for full explanation → in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Conditions: Metastatic Non-small Cell Lung Cancer With MTAP Deletion
Interventions: BMS-986504, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel
NCT07063745 - View on ClinicalTrials.gov →